Literature DB >> 22699677

CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.

Karen Brajão de Oliveira1, Roberta Losi Guembarovski, Alda Maria Fiorina Losi Guembarovski, Ana Cristina da Silva do Amaral Herrera, Walter Jorge Sobrinho, Carolina Batista Ariza, Maria Angelica Ehara Watanabe.   

Abstract

Signals from the microenvironment have a profound influence on the maintenance or progression of breast cancer. In the present study, the frequency of CXCL12 rs1801157 polymorphism in peripheral blood and the expression of CXCL12, CXCR4 and IFNγ mRNA in normal and mammary gland tumor tissues were assessed in breast cancer patients. Genotyping was performed by polymerase chain reaction followed by restriction fragment length polymorphism and expression analyses by quantitative RT-PCR. A lower CXCL12 mRNA relative expression was observed among allele A carriers when compared to GG carriers (p = 0.012). ER-positive breast cancer allele A carriers showed a significantly lower expression of CXCL12 mRNA within tumor tissue than in normal breast tissue when compared to GG ER-positive patients (p = 0.016). CXCR4 mRNA (p < 0.001) and CXCL12 mRNA (p = 0.02) relative expressions were significantly correlated with relative IFNγ mRNA expression. Allele A carriers presenting high levels of IFNγ had a significantly higher expression of CXCR4 mRNA in tumor tissue than GG patients (p = 0.026). It is possible that allele A carrier hormone receptor-positive patients could be more susceptible to metastasis development, since they present a lower CXCL12 expression in tumor tissue, and tumor cells expressing CXCR4 could migrate toward CXCL12 gradient. IFNγ expression increases in order to improve immune response and could favor higher CXCR4 expression leading to migration of cells, possibly of metastatic ones, too.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699677     DOI: 10.1007/s10238-012-0194-5

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  43 in total

1.  Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.

Authors:  Takayuki Kobayashi; Hitoshi Tsuda; Tomoyuki Moriya; Tamio Yamasaki; Ryoko Kikuchi; Shigeto Ueda; Jiro Omata; Junji Yamamoto; Osamu Matsubara
Journal:  Breast Cancer Res Treat       Date:  2009-12-18       Impact factor: 4.872

2.  Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.

Authors:  Julie M Hall; Kenneth S Korach
Journal:  Mol Endocrinol       Date:  2003-02-13

3.  CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients.

Authors:  Karen Brajão de Oliveira; Roberta Losi Guembarovski; Julie Massayo Maeda Oda; Mário Sérgio Mantovani; Clisia Mara Carrera; Edna Maria Vissoci Reiche; Julio Cesar Voltarelli; Ana Cristina da Silva do Amaral Herrera; Maria Angelica Ehara Watanabe
Journal:  Cytokine       Date:  2011-05-17       Impact factor: 3.861

4.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

Authors:  Koei Chin; Sandy DeVries; Jane Fridlyand; Paul T Spellman; Ritu Roydasgupta; Wen-Lin Kuo; Anna Lapuk; Richard M Neve; Zuwei Qian; Tom Ryder; Fanqing Chen; Heidi Feiler; Taku Tokuyasu; Chris Kingsley; Shanaz Dairkee; Zhenhang Meng; Karen Chew; Daniel Pinkel; Ajay Jain; Britt Marie Ljung; Laura Esserman; Donna G Albertson; Frederic M Waldman; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

Review 5.  The chemokine receptors CXCR4 and CXCR3 in cancer.

Authors:  Amy M Fulton
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

6.  CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

Authors:  Karen Brajão de Oliveira; Julie Massayo Maeda Oda; Julio Cesar Voltarelli; Thiago Franco Nasser; Mario Augusto Ono; Thiago Cezar Fujita; Tiemi Matsuo; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

7.  Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer.

Authors:  Saima Hassan; Andrea Baccarelli; Ombretta Salvucci; Mark Basik
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

Review 8.  Genetic determinants of cancer metastasis.

Authors:  Don X Nguyen; Joan Massagué
Journal:  Nat Rev Genet       Date:  2007-05       Impact factor: 53.242

Review 9.  Molecular markers for predicting response to tamoxifen in breast cancer patients.

Authors:  D R Ciocca; R Elledge
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.925

10.  Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer.

Authors:  Hua Kang; Gareth Watkins; Christian Parr; Anthony Douglas-Jones; Robert E Mansel; Wen G Jiang
Journal:  Breast Cancer Res       Date:  2005-04-04       Impact factor: 6.466

View more
  12 in total

1.  CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer.

Authors:  Alda Losi Guembarovski; Roberta Losi Guembarovski; Bruna Karina Banin Hirata; Glauco Akelinghton Freire Vitiello; Karen Mayumi Suzuki; Mayara Tiemi Enokida; Maria Angelica Ehara Watanabe; Edna Maria Vissoci Reiche
Journal:  Mol Biol Rep       Date:  2018-06-20       Impact factor: 2.316

2.  Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis.

Authors:  Yong-Jiang Li; Yi-Ling Dai; Wen-Biao Zhang; Shuang-Jiang Li; Chong-Qi Tu
Journal:  Clin Exp Med       Date:  2015-12-17       Impact factor: 3.984

Review 3.  Immunohistochemical expression of CXCR4 on breast cancer and its clinical significance.

Authors:  Marina Okuyama Kishima; Carlos Eduardo Coral de Oliveira; Bruna Karina Banin-Hirata; Roberta Losi-Guembarovski; Karen Brajão de Oliveira; Marla Karine Amarante; Maria Angelica Ehara Watanabe
Journal:  Anal Cell Pathol (Amst)       Date:  2015-06-16       Impact factor: 2.916

4.  A single nucleotide polymorphism in the stromal cell-derived factor 1 gene is associated with coronary heart disease in Chinese patients.

Authors:  Lei Feng; Shi-Yan Nian; Ying-Lu Hao; Wen-Bo Xu; Dan Ye; Xing-Feng Zhang; Dan Li; Lei Zheng
Journal:  Int J Mol Sci       Date:  2014-06-19       Impact factor: 5.923

5.  Preferential, enhanced breast cancer cell migration on biomimetic electrospun nanofiber 'cell highways'.

Authors:  Mark Tyler Nelson; Aaron Short; Sara L Cole; Amy C Gross; Jessica Winter; Tim D Eubank; John J Lannutti
Journal:  BMC Cancer       Date:  2014-11-10       Impact factor: 4.430

6.  The CXCL12 G801A polymorphism is associated with cancer risk: a meta-analysis.

Authors:  Ke Zhu; Benchun Jiang; Rong Hu; Ying Yang; Miao Miao; Yingchun Li; Zhuogang Liu
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

7.  Wilms' tumor susceptibility: possible involvement of FOXP3 and CXCL12 genes.

Authors:  Patricia Midori Murobushi Ozawa; Carolina Batista Ariza; Roberta Losi-Guembarovski; Alda Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Bruna Karina Banin-Hirata; Marina Okuyama Kishima; Diego Lima Petenuci; Maria Angelica Ehara Watanabe
Journal:  Mol Cell Pediatr       Date:  2016-11-10

Review 8.  qPCR primer design revisited.

Authors:  Stephen Bustin; Jim Huggett
Journal:  Biomol Detect Quantif       Date:  2017-11-22

9.  Effects of miR-338 on morphine tolerance by targeting CXCR4 in a rat model of bone cancer pain.

Authors:  Hong-Xia Mei; Min-Hong Zhou; Xing-Wang Zhang; Xi-Xi Huang; Yong-Le Wang; Pei-Fang Wang; Gong-Hao Zhan
Journal:  Biosci Rep       Date:  2017-03-15       Impact factor: 3.840

Review 10.  CC chemokine receptor 5: the interface of host immunity and cancer.

Authors:  Carlos Eduardo Coral de Oliveira; Julie Massayo Maeda Oda; Roberta Losi Guembarovski; Karen Brajão de Oliveira; Carolina Batista Ariza; Jamil Soni Neto; Bruna Karina Banin Hirata; Maria Angelica Ehara Watanabe
Journal:  Dis Markers       Date:  2014-01-19       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.